当前位置: X-MOL 学术ACS Pharmacol. Transl. Sci. › 论文详情
Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.
ACS Pharmacology & Translational Science Pub Date : 2019-08-16 , DOI: 10.1021/acsptsci.9b00041
Jihong Li,Yoshiyuki Fukase,Yi Shang,Wei Zou,José M Muñoz-Félix,Lorena Buitrago,Johannes van Agthoven,Yixiao Zhang,Ryoma Hara,Yuta Tanaka,Rei Okamoto,Takeshi Yasui,Takashi Nakahata,Toshihiro Imaeda,Kazuyoshi Aso,Yuchen Zhou,Charles Locuson,Dragana Nesic,Mark Duggan,Junichi Takagi,Roger D Vaughan,Thomas Walz,Kairbaan Hodivala-Dilke,Steven L Teitelbaum,M Amin Arnaout,Marta Filizola,Michael A Foley,Barry S Coller

The integrin αVβ3 receptor has been implicated in several important diseases, but no antagonists are approved for human therapy. One possible limitation of current small-molecule antagonists is their ability to induce a major conformational change in the receptor that induces it to adopt a high-affinity ligand-binding state. In response, we used structural inferences from a pure peptide antagonist to design the small-molecule pure antagonists TDI-4161 and TDI-3761. Both compounds inhibit αVβ3-mediated cell adhesion to αVβ3 ligands, but do not induce the conformational change as judged by antibody binding, electron microscopy, X-ray crystallography, and receptor priming studies. Both compounds demonstrated the favorable property of inhibiting bone resorption in vitro, supporting potential value in treating osteoporosis. Neither, however, had the unfavorable property of the αVβ3 antagonist cilengitide of paradoxically enhancing aortic sprout angiogenesis at concentrations below its IC50, which correlates with cilengitide’s enhancement of tumor growth in vivo.
更新日期:2019-08-18

 

全部期刊列表>>
物理学研究前沿热点精选期刊推荐
chemistry
《自然》编辑与您分享如何成为优质审稿人-信息流
欢迎报名注册2020量子在线大会
化学领域亟待解决的问题
材料学研究精选新
GIANT
自然职场线上招聘会
科研绘图
ACS ES&T Engineering
ACS ES&T Water
屿渡论文,编辑服务
阿拉丁试剂right
张晓晨
田蕾蕾
李闯创
刘天飞
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
天合科研
x-mol收录
X-MOL
苏州大学
廖矿标
深圳湾
试剂库存
down
wechat
bug